Commercial Credit Report for BioPorto A/S

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for BioPorto A/S is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	BioPorto A/S
Tuborg Havnevej 15, St.
Phone: +45 45290000p:+45 45290000	HELLERUP, 2900 Denmark	Ticker: BIOPORBIOPOR

Business Summary

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2024	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2835	In vitro and in vivo diagnostic substances
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairman of the Board	JohnMcdonough		1/1/2024	1/1/2024
Group Chief Executive Officer	PeterMoerch Eriksen	64	4/30/2024	7/18/2013
Vice Chairman of the Board	Torben A.Nielsen	56	4/10/2014	4/2/2013
6 additional Officers and Directors records available in full report.

Business Names

Business Name
0JJM
2P4
BIOPOR
Bioporto A/S
Realinvest.dk A/S

General Information

Number of Employees:	33	(As of 6/30/2024)
Outstanding Shares:	429,657,461	(As of 6/30/2024)
Shareholders:	20,486
Stock Exchange:	CPH
Fax Number:	+45 45290001

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN